Načítá se...
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo—Brief Report
OBJECTIVE: Although early proof-of-concept studies of somatic in vivo genome editing of the mouse ortholog of proprotein convertase subtilisin/kexin type 9 (Pcsk9) in mice have established its therapeutic potential for the prevention of cardiovascular disease, the unique nature of genome-editing tec...
Uloženo v:
| Vydáno v: | Arterioscler Thromb Vasc Biol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4850082/ https://ncbi.nlm.nih.gov/pubmed/26941020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.116.307227 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|